Literature DB >> 11282270

In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.

J C Rodríguez1, M Ruiz, A Climent, G Royo.   

Abstract

The in vitro activity of ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin against strains of Mycobacterium tuberculosis was studied. Moxifloxacin and levofloxacin showed the greatest activity having an MIC(90) of 1 mg/l. The MIC(90) for ofloxacin was 2 mg/l and for ciprofloxacin 4 mg/l. Further studies should be made to determine the role played by these compounds in the treatment of tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11282270     DOI： 10.1016/s0924-8579(00)00337-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  17 in total

1.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 3.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Authors:  Natasha Van't Boveneind-Vrubleuskaya; Tatiana Seuruk; Kai van Hateren; Tridia van der Laan; Jos G W Kosterink; Tjip S van der Werf; Dick van Soolingen; Susan van den Hof; Alena Skrahina; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm.

Authors:  F Masselot; A Boulos; M Maurin; J M Rolain; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 6.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

7.  Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.

Authors:  Cynthia A Sanders; Rachel R Nieda; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

9.  Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.

Authors:  Ricky W T Lau; Pak-Leung Ho; Richard Y T Kao; Wing-Wai Yew; Terrence C K Lau; Vincent C C Cheng; Kwok-Yung Yuen; Stephen K W Tsui; Xinchun Chen; Wing-Cheong Yam
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

10.  Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Authors:  Rose A Devasia; Amondrea Blackman; Carolyn May; Svetlana Eden; Teresa Smith; Nancy Hooper; Fernanda Maruri; Charles Stratton; Ayumi Shintani; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2009-03-28       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.